Polymorphic Variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and Dopamine D2 and D3 Receptors and Their Association With Tardive Dyskinesia in Severe Mental Illness

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2005-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/01.jcp.0000177546.34799.afPMID 16160620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.

  2005cited by this paper
• The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.

  2005cited by this paper
• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population

  2004cited by this paper
• On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation.

  2004cited by this paper
• Cytochrome P-450 2D6*10 C188T Polymorphism Is Associated with Antipsychotic-Induced Persistent Tardive Dyskinesia in Chinese Schizophrenic Patients

  2004cited by this paper
• Reversal of Reserpine-Induced Orofacial Dyskinesia and Cognitive Dysfunction by Quercetin

  2004cited by this paper
• Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships.

  2003influential reference
• Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients

  2003cited by this paper
• The importance of glutathione in human disease.

  2003cited by this paper
• CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.

  2003cited by this paper
• Genetic polymorphisms of the human MDR1 drug transporter.

  2003cited by this paper
• Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia

  2003cited by this paper
• Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection

  2003cited by this paper
• Semiquinone radical intermediate in catecholic estrogen-mediated cytotoxicity and mutagenesis: Chemoprevention strategies with antioxidants

  2003cited by this paper
• CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.

  2003cited by this paper
• Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia

  2003cited by this paper
• A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy.

  2003influential reference
• Chlorpromazine equivalent doses for the newer atypical antipsychotics.

  2003cited by this paper
• A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression

  2002cited by this paper
• In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

  2002cited by this paper
• Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism

  2002cited by this paper
• Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics

  2002cited by this paper
• Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia.

  2001cited by this paper
• Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs.

  2001cited by this paper
• Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia: Relation to Tardive Dyskinesia

  2000cited by this paper
• CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

  2000cited by this paper
• The Current Status of Tardive Dyskinesia

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

  1997cited by this paper
• A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia.

  1997cited by this paper
• Power and precision : a computer program for statistical power analysis and confidence intervals

  1997cited by this paper
• Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes.

  1997cited by this paper
• Schizophrenia, tardive dyskinesia, and a D3 receptor gene variant: a new twist on dyskinesias?

  1997cited by this paper
• Association of dopamine D2 receptor molecular variant with schizophrenia.

  1994cited by this paper
• Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes.

  1992cited by this paper
• Glutathione S-transferases.

  1990cited by this paper
• The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients

  1987influential reference
• Research diagnoses for tardive dyskinesia.

  1982cited by this paper
• [Chemotherapy in psychiatry].

  1969cited by this paper

• Differential DNA methylation and gene expression in stem cell-derived cardiomyocytes from patients with and without a history of clozapine-induced myocarditis

  2025cites this paper
• Genetic markers of pharmacokinetic features in patients with a severe outcome of schizophrenia, resistant to antipsychotic therapy

  2023cites this paper
• UKnowledge UKnowledge

  2022cites this paper
• Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies

  2022cites this paper
• Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside

  2021cites this paper
• Pathophysiological mechanisms underlying antipsychotic-induced tardive dyskinesia

  2020cites this paper
• Edentulousness in severely mentally ill patients: A pilot study of sex-specific patterns for risk factors including the glutathione S-transferase M1 gene.

  2020cites this paper
• The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis

  2020cites this paper
• Pharmacogenomics in Psychiatric Disorders

  2019cites this paper
• Glutathione S-transferase is a good biomarker in acrylamide induced neurotoxicity and genotoxicity

  2018cites this paper
• CYP/PON genetic variations as determinant of organophosphate pesticides toxicity

  2017cites this paper
• The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions

  2017cites this paper
• Pharmacogenetics of Serious Antipsychotic Side Effects

  2016cites this paper
• Pharmacogenetics of the Efficacy of Antipsychotic Drugs in Schizophrenia

  2016cites this paper
• Clinical Utility and Economic Impact of CYP2D6 Genotyping.

  2016cites this paper
• Pharmacogenetics of tardive dyskinesia: an updated review of the literature.

  2016cites this paper
• CYP2D6 polymorphisms and their influence on risperidone treatment

  2016cites this paper
• Pharmacogenetic studies of drug response in schizophrenia

  2016cites this paper
• Фармакогенетический подход к оценке риска развития индуцированных антипсихотиками экстрапирамидных нарушений

  2015cites this paper
• Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort

  2015influential citation
• Association between Antipsychotic-Induced Restless Legs Syndrome and Glutathione S-Transferase Gst-M1, Gst-T1 and Gst-P1 Gene Polymorphisms

  2015cites this paper
• [Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].

  2015cites this paper
• Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?

  2014cites this paper
• CYP2D6 : clinical implications in neuropsychiatry

  2014cites this paper
• Genetics of essential tremor: from phenotype to genes, insights from both human and mouse studies.

  2014cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Associations between hypothalamic-pituitary-adrenal axis system gene variants and cortisol reactivity in preschoolers: Main effects and gene-environment interactions

  2014cites this paper
• EPA-1239 – Individualizing Clozapine and Risperidone Treatment For Schizophrenia Patients

  2014cites this paper
• Pharmacogenetics of Antipsychotics

  2014cites this paper
• Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.

  2013cites this paper
• A genetic dissection of antipsychotic induced movement disorders.

  2013cites this paper
• CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence.

  2013cites this paper
• Pharmacogenetics of Risperidone: A Systematic Review of the Clinical Effects of CYP2D6 Polymorphisms

  2013cites this paper
• Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy

  2013cites this paper
• There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients

  2013cites this paper
• Farmacogenética de las reacciones adversas a los antipsicóticos en pacientes con esquizofrenia

  2012cites this paper
• Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis

  2012cites this paper
• Drug Selection in Psychiatry

  2012cites this paper
• Pharmacogenetics in Psychiatry

  2012cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia

  2011cites this paper
• Relationship between P-glycoprotein and second-generation antipsychotics.

  2011cites this paper
• No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients

  2011cites this paper
• Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

  2011cites this paper
• Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

  2011cites this paper
• Pharmacogenomic testing to guide treatment using antipsychotic medications

  2011cites this paper
• Genetics of tardive dyskinesia.

  2011cites this paper
• Protective Effect of Curcumin and its Combination with Piperine (Bioavailability Enhancer) Against Haloperidol-Associated Neurotoxicity: Cellular and Neurochemical Evidence

  2011cites this paper
• Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients

  2011cites this paper
• Pharmacogenetics of Response to Antipsychotics in Patients with Schizophrenia

  2011cites this paper
• Personalized antipsychotic treatment: the adverse effects perspectives.

  2010cites this paper
• Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.

  2010cites this paper
• ANTIPSYCHOTIC-INDUCED VACUOUS CHEWING MOVEMENTS AND EXTRAPYRAMIDAL SIDE-EFFECTS ARE HIGHLY HERITABLE IN MICE

  2010cites this paper
• Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry.

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: Preliminary findings

  2010cites this paper
• Pharmacogenetics and schizophrenia.

  2010cites this paper
• The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.

  2010cites this paper
• Association study of serotonergic gene variants with antipsychotic-induced adverse reactions

  2009cites this paper
• Monozygotic female twins discordant for phenotype of Wilson's disease

  2009cites this paper
• The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A meta‐analysis

  2009influential citation
• Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients

  2009cites this paper
• Subthalamic nucleus deep brain stimulation for camptocormia associated with Parkinson's disease

  2009cites this paper
• The future (or lack of future) of personalized prescription in psychiatry.

  2009cites this paper
• DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping

  2009cites this paper
• MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis.

  2009cites this paper
• Association study between glutathione S‐transferase GST‐M1, GST‐T1, and GST‐P1 polymorphisms and tardive dyskinesia

  2009cites this paper
• Farmacogenética da esquizofrenia

  2009cites this paper
• Pharmacovigilance in psychiatry: pharmacogenetic tests and therapeutic drug monitoring are promising tools

  2008cites this paper
• Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

  2008cites this paper
• Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions

  2008cites this paper
• Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.

  2008cites this paper
• Gene Association Studies of Schizophrenia and Tardive Dyskinesia

  2008cites this paper
• A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I.

  2008cites this paper
• An investigation of the α1A‐adrenergic receptor gene and antipsychotic‐induced side‐effects

  2008cites this paper
• Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European–Brazilian schizophrenics

  2008cites this paper
• Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.

  2008cites this paper
• A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II.

  2008cites this paper
• Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians

  2007cites this paper
• Pharmacogenetics of risperidone response and induced side effects.

  2007cites this paper
• Genetic association analysis of polymorphisms in four cytochrome P450 genes, the MDR1 gene and treatment-outcome in Xhosa schizophrenia patients

  2007cites this paper
• Pharmacogenetics and schizophrenia.

  2007cites this paper
• Association between tardive dyskinesia and dopamine receptor genes among patients with chronic schizophrenia

  2007cites this paper
• Association of genetic variants and the susceptibility to abnormal involuntary movements and tardive dyskinesia (TD) in Xhosa schizophrenia patients

  2007cites this paper
• Pharmacogenomics in Psychiatry

  2007cites this paper
• A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

  2007cites this paper
• A Study of Genetic (CYP2D6 and ABCB1) and Environmental (Drug Inhibitors and Inducers) Variables That May Influence Plasma Risperidone Levels

  2007cites this paper
• Pharmacogenetic Studies Investigating the Adverse Effects of Antipsychotics

  2007cites this paper
• Genetics of essential tremor.

  2007influential citation
• PHARMACOGENETIQUE DE LA SCHIZOPHRENIE

  2007cites this paper
• Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms

  2007cites this paper
• Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.

  2007cites this paper
• The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study.

  2007cites this paper
• No association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and schizophrenia in a Spanish sample

  2007cites this paper
• Individualizing antipsychotic drug therapy in schizophrenia: The promise of pharmacogenetics

  2007cites this paper
• Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

  2007cites this paper
• Pharmacogenetics and Pharmacogenomics in Psychiatry: Clinical Applications

  2007cites this paper
• The effect of atypical versus typical antipsychotics on tardive dyskinesia

  2006influential citation
• Tardive dyskinesia and essential fatty acids

  2006cites this paper